A randomized phase II study of anti-PD-1 antibody [MK-3475 (pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced Merkel cell carcinoma (Alliance A091605)
- Citation:
- J Clin Oncol vol 36 (15_suppl) TPS9599-TPS9599
- Meeting Instance:
- ASCO 2018
- Year:
- 2018
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Radiation Onc
- Pharmas:
- Merck
- Grants:
- U10CA180821, U10CA180882; U10CA180868, U10CA180888, U24CA196171
- Corr. Author:
- Authors:
- Jason Luke Steven Chmura Joseph Salama Hania Al-Hallaq Charles Hsu Sue Yom Mark Kozloff Jacob Allred Pamela Munster Gary Schwartz
- Networks:
- CA824, COLUMBIA, LAPS-IL057, LAPS-MN026, LAPS-NC010, LAPS-PA015
- Study
- Alliance-A091605
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: